Eyepoint Pharmaceuticals (EYPT) FDA Approvals $0.43 0.00 (-0.93%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Upcoming FDA Events for Eyepoint Pharmaceuticals Eyepoint Pharmaceuticals (EYPT) has upcoming FDA regulatory milestones for DURAVYU. The table below outlines estimated target dates and event types for these pending regulatory actions. DrugTarget DateAnnouncement DURAVYUQ4 2026Top-line dataEyePoint, Inc. announced that the Topline data from LUCIA, the second pivotal Phase 3 clinical trial in wet AMD, expected in Q4 2026 (August 17, 2026) DURAVYUH1 2027NDA submissionEyePoint, Inc. announced that the potential FDA New Drug Application submission planned for 1H 2027 (August 17, 2026) DURAVYUQ4 2027Top-line dataEyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quarter of 2027. (July 30, 2026) Eyepoint Pharmaceuticals' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Eyepoint Pharmaceuticals (EYPT). Over the past two years, Eyepoint Pharmaceuticals has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as DURAVYU. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. DURAVYU FDA Regulatory Timeline and Events DURAVYU is a drug developed by Eyepoint Pharmaceuticals for the following indication: In patients with non-proliferative diabetic retinopathy (NPDR). This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Positive Results - October 19,2026Positive Results Phase 3Drug: DURAVYUAnnounced Date: October 19, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).Read AnnouncementNDA submission - August 17,2026Nda Submission Drug: DURAVYUAnnounced Date: August 17, 2026Target Action Date: H1 2027Estimated Target Date Range: January 1, 2027 - June 30, 2027Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the potential FDA New Drug Application submission planned for 1H 2027Read AnnouncementTop-line data - August 17,2026Top-Line Data Drug: DURAVYUAnnounced Date: August 17, 2026Target Action Date: Q4 2026Estimated Target Date Range: October 1, 2026 - December 31, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the Topline data from LUCIA, the second pivotal Phase 3 clinical trial in wet AMD, expected in Q4 2026Read AnnouncementTop-line results - August 17,2026Top-Line Results Phase 3Drug: DURAVYUAnnounced Date: August 17, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).Read AnnouncementTop-line data - July 30,2026Top-Line Data Drug: DURAVYUAnnounced Date: July 30, 2026Target Action Date: Q4 2027Estimated Target Date Range: October 1, 2027 - December 31, 2027Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quarter of 2027.AI SummaryEyePoint, Inc. announced that its COMO and CAPRI clinical trials for DURAVYU in diabetic macular edema (DME) rapidly enrolled more than 480 participants within five months. The company said the strong enrollment reflects continued interest from retinal specialists and patients in participating in DURAVYU studies. Topline 56-week data from both DME trials are anticipated in the fourth quarter of 2027. These results are expected to provide important information about DURAVYU’s effectiveness and safety over nearly one year of treatment. DURAVYU is being studied as a potential long-acting treatment for DME, a condition in which diabetes causes swelling in the retina and can impair vision. Earlier clinical studies of DURAVYU in wet age-related macular degeneration and DME reported stable vision and control of retinal anatomy after a single dose. EyePoint is developing the treatment in partnership with the retina community and aims to reduce treatment burdens for patients who may require repeated eye injections.Read AnnouncementEnrollment Update - July 30,2026Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: July 30, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced it has completed enrollment in COMO and CAPRI, the two global Phase 3 clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). Over 480 patients have been enrolled across both trials, with full enrollment occurring ahead of schedule, in only five months.AI SummaryEyePoint, Inc. announced that it has completed enrollment in COMO and CAPRI, two global Phase 3 clinical trials evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). Together, the trials enrolled more than 480 patients in just five months, finishing ahead of schedule. The rapid enrollment reflects strong interest in participating among retinal specialists and patients. Topline results from both studies are expected in the fourth quarter of 2027, after 56 weeks of follow-up. DURAVYU is designed to provide localized treatment in the eye and is being studied for its potential to help control vision loss and retinal changes linked to DME. Earlier Phase 1 and Phase 2 studies in DME and wet age-related macular degeneration showed stable vision and anatomical control after a single dose, with no safety signals reported in more than 190 patients across four completed trials. DURAVYU remains investigational and is not approved for use.Read Announcementreview - May 14,2026Review Data Safety Monitoring Committee (DSMC)Drug: DURAVYUAnnounced Date: May 14, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled review of the Company's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD) and recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications.AI SummaryEyePoint, Inc. said the independent Data Safety Monitoring Committee finished its third scheduled review of the Phase 3 DURAVYU program for wet age-related macular degeneration and recommended that both the LUGANO and LUCIA trials continue as planned, with no changes to the study design. The company said the masked data still show a favorable safety profile, matching results from four earlier clinical trials. It also noted that all active patients in the treatment group have reached their second dosing visit, and more than 35% have received a third dose. EyePoint said LUGANO topline data are still expected in mid-2026, with LUCIA results to follow soon after. DURAVYU remains an investigational treatment and has not been approved. The company said earlier studies showed stable vision and eye anatomy control, with no drug-related safety concerns seen in more than 190 patients.Read AnnouncementDose Update - March 2,2026Dose Update Phase 3Drug: DURAVYUAnnounced Date: March 2, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).AI SummaryEyePoint, Inc. announced the first patient has been dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). The company is running active Phase 3 programs for DURAVYU in wet age-related macular degeneration (wet AMD) and DME, two of the largest multi‑billion‑dollar retinal disease markets. These global studies aim to confirm the treatment’s benefit for patients with vision-threatening retinal disease. Topline data for DURAVYU in DME is anticipated in the second half of 2027. Earlier Phase 1 and 2 trials showed safety and efficacy signals, with single-dose treatment demonstrating stability in vision and anatomical control. Across four completed trials involving over 190 patients, no safety signals were observed. EyePoint states it remains focused on working with the retina community to advance this investigational treatment. Read Announcementreview - November 19,2025Review Data Safety Monitoring Committee (DSMC)Drug: DURAVYUAnnounced Date: November 19, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced that the independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the Company's ongoing pivotal Phase 3 program evaluating DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).AI SummaryEyePoint Pharmaceuticals said an independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the pivotal Phase 3 program testing DURAVYU for wet age-related macular degeneration (wet AMD). As of the Sept. 29, 2025 data cutoff, all patients in the LUGANO and LUCIA trials had reached the Week 8 visit, when DURAVYU arms received their initial dose, and about 25% had received the planned second dose at Week 32. The DSMC recommended both trials continue as planned with no protocol changes. Masked safety data showed no safety signals and were consistent with earlier clinical trials. LUGANO and LUCIA are randomized, double‑masked, aflibercept‑controlled, non‑inferiority Phase 3 trials with enrollment complete (over 900 patients). Patients were randomized 1:1 to DURAVYU 2.7 mg every six months or on‑label aflibercept. EyePoint remains on track to report topline 56‑week LUGANO results in mid‑2026, with LUCIA results to follow closely. The DSMC meets every six months per protocol to monitor participant safety.Read AnnouncementProvided Update - October 14,2025Provided Update Phase 3Drug: DURAVYUAnnounced Date: October 14, 2025Target Action Date: Q1 2026Estimated Target Date Range: January 1, 2026 - March 31, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced details for its pivotal Phase 3 program evaluating DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME) with first patient dosing anticipated in first quarter of 2026.AI SummaryEyePoint Pharmaceuticals announced its pivotal Phase 3 clinical program for DURAVYU™ (vorolanib intravitreal insert) to treat diabetic macular edema (DME), with first patient dosing expected in the first quarter of 2026. The program will include two identical non-inferiority trials, COMO and CAPRI, each enrolling about 240 patients. Both treatment-naïve and previously treated patients will be randomly assigned to a 2.7 mg DURAVYU arm or a 2 mg aflibercept control, with redosing every six months. The primary endpoint is the change from baseline in best corrected visual acuity (BCVA) at weeks 52 and 56 compared to aflibercept. New preclinical data show that vorolanib blocks vascular endothelial growth factor (VEGF)–mediated leakage and inhibits interleukin-6 (IL-6)–driven inflammation through JAK-1 receptor inhibition. This dual action supports the early and sustained improvements seen in the Phase 2 VERONA trial and highlights DURAVYU as a potential six-month, multi-mechanism treatment option for DME patients.Read AnnouncementEnrollment Update - July 29,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: July 29, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced it has completed enrollment of its Phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal non-inferiority trials evaluating DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD). The first pivotal trial, LUGANO, completed enrollment in May 2025.AI SummaryEyePoint Pharmaceuticals has finished enrolling the LUCIA trial, the second of two Phase 3 non-inferiority studies testing DURAVYU for wet age-related macular degeneration. The first trial, LUGANO, completed enrollment in May 2025. LUCIA enrolled over 400 patients in seven months, bringing the combined total to more than 800 and making it one of the fastest Phase 3 wet AMD programs. An independent Data Safety Monitoring Committee reviewed interim safety data and saw no new risks. They confirmed the trials should continue as planned. DURAVYU’s safety profile remained consistent with earlier clinical studies, with no drug-related serious eye or systemic adverse events reported. EyePoint expects interim data from LUGANO’s 56-week analysis in mid-2026, with LUCIA topline results soon after. Both trials test six-month dosing of DURAVYU versus on-label aflibercept, measuring vision, safety, and treatment burden.Read AnnouncementEnrollment Update - May 27,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: May 27, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced it has enrolled and randomized over 400 patients in the Phase 3 LUGANO pivotal trial of DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD) exceeding its enrollment target.AI SummaryEyePoint Pharmaceuticals has surpassed its enrollment target in the Phase 3 LUGANO pivotal trial for DURAVYU™, a sustained-release treatment for wet age-related macular degeneration (wet AMD). More than 400 patients have been enrolled and randomized over a seven-month period—a record pace for a Phase 3 trial in this field. This rapid enrollment reflects strong interest from both physicians and patients, highlighting the significant need for improved treatment options in wet AMD. The LUGANO trial, which is one of two non-inferiority trials in EyePoint’s Phase 3 program for DURAVYU, aims to assess the drug’s safety and efficacy. With top-line 56-week data expected in mid-2026, the timely progress of this trial, along with the upcoming LUCIA trial enrollment, underscores the potential impact of DURAVYU in transforming the current treatment paradigm for wet AMD.Read AnnouncementProvided Update - March 5,2025Provided Update Drug: DURAVYUAnnounced Date: March 5, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc highlighted recent corporate developments.AI SummaryEyePoint Pharmaceuticals, Inc. recently announced its financial results for Q4 and the full year ended December 31, 2024, along with key corporate developments. The company emphasized that its sustained delivery therapy, DURAVYU™, is progressing well in clinical trials for two major retinal diseases. The Phase 3 wet AMD trials, LUGANO and LUCIA, are exceeding enrollment expectations, with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule. Positive Phase 2 data from the VERONA trial in diabetic macular edema also met primary and secondary endpoints. Additionally, EyePoint highlighted its strong financial position, reporting $371 million in cash and investments as of December 31, 2024, which is expected to support operations into 2027. These developments underscore the company’s commitment to advancing DURAVYU™ and position it for potential future regulatory and commercial success.Read AnnouncementEnrollment Update - February 25,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: February 25, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced that Jay S. Duker, M.D., EyePoint's President and CEO, will present an update on enrollment for its ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD) and additional subgroup analyses for the Phase 2 VERONA trial for DURAVYU in diabetic macular edema (DME) at the TD Cowen 45th Annual Health Care Conference.AI SummaryEyePoint Pharmaceuticals announced that its President and CEO, Dr. Jay S. Duker, will share updates on DURAVYU™ during a corporate presentation. The presentation is set for Tuesday, March 4, 2025 at 9:10 a.m. ET at the TD Cowen 45th Annual Health Care Conference. Dr. Duker will provide an update on enrollment for the ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD). Additionally, he will discuss subgroup analyses from the Phase 2 VERONA trial, which tested DURAVYU for diabetic macular edema (DME). This update is important as it gives insight into the progress of the clinical trials for DURAVYU, an investigational product aimed at treating serious retinal diseases. The live webcast and archived presentation can be accessed on the company’s website. Read AnnouncementProvided Update - February 5,2025Provided Update Phase 3Drug: DURAVYUAnnounced Date: February 5, 2025Target Action Date: LATE 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025AI SummaryEyePoint Pharmaceuticals has reported encouraging Phase 2 results for its investigational therapy DURAVYU, a sustained delivery treatment for diabetic macular edema. In the trial, both investigated doses met the primary endpoint by extending the time to a needed supplemental injection compared to the current treatment. In particular, the 2.7mg dose showed early and sustained improvements in vision and retinal anatomy while also reducing the overall treatment burden. The positive outcomes were paired with a favorable safety profile, with no serious ocular or systemic adverse events related to DURAVYU. Building on these promising findings, the company anticipates launching a Phase 3 non-inferiority pivotal clinical program by the end of 2025, aiming to further validate DURAVYU’s potential as a best-in-class treatment option for serious retinal diseases.Read AnnouncementPositive Results - February 5,2025Positive Results Phase 2Drug: DURAVYUAnnounced Date: February 5, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor (TKI) formulated in proprietary bioerodible Durasert E™.AI SummaryEyePoint Pharmaceuticals announced positive six-month results from the ongoing Phase 2 VERONA trial evaluating DURAVYU™, an investigational sustained delivery therapy that uses patent-protected vorolanib delivered via its proprietary bioerodible Durasert E™ system. Both tested doses, 1.34 mg and 2.7 mg, achieved the primary endpoint by extending the time to the first supplemental injection compared to an aflibercept control. The 2.7 mg dose, in particular, showed an early and sustained improvement in visual acuity with a 7.1-letter gain in BCVA at 24 weeks, along with a 76-micron reduction in central subfield thickness. The study also reported a significant decrease in treatment burden and maintained a favorable safety profile with no observed DURAVYU-related ocular or systemic serious adverse events. These promising outcomes support plans to initiate a Phase 3 non-inferiority pivotal program later in 2025.Read AnnouncementDose Update - December 4,2024Dose Update Phase 3Drug: DURAVYUAnnounced Date: December 4, 2024Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced that the first patient has been dosed in the LUCIA trial, the Company's second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD).AI SummaryEyePoint Pharmaceuticals has dosed the first patient in the LUCIA trial, its second global Phase 3 study for DURAVYU (formerly EYP-1901) in treating wet age-related macular degeneration (wet AMD). DURAVYU is an investigational therapy that delivers vorolanib steadily through a bioerodible implant. The new trial follows closely on the heels of the ongoing LUGANO trial, demonstrating the company’s strong commitment to exploring sustained drug delivery for retinal diseases. The LUCIA trial aims to gather data on the drug’s safety, effectiveness, and dosing flexibility, potentially easing the treatment burden for wet AMD patients who often require frequent injections. With enthusiastic support from physicians and patients around the globe, EyePoint is optimistic that these Phase 3 trials will help change the current treatment landscape for wet AMD and offer more durable treatment options.Read Announcement Eyepoint Pharmaceuticals FDA Events - Frequently Asked Questions Has Eyepoint Pharmaceuticals received FDA approval? As of now, Eyepoint Pharmaceuticals (EYPT) has not received any FDA approvals for its therapy in the last two years. What drugs has Eyepoint Pharmaceuticals submitted to the FDA? In the past two years, Eyepoint Pharmaceuticals (EYPT) has reported FDA regulatory activity for DURAVYU. What is the most recent FDA event for Eyepoint Pharmaceuticals? The most recent FDA-related event for Eyepoint Pharmaceuticals occurred on October 19, 2026, involving DURAVYU. The update was categorized as "Positive Results," with the company reporting: "EyePoint, Inc. announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD)." What conditions do Eyepoint Pharmaceuticals' current drugs treat? Currently, Eyepoint Pharmaceuticals has one therapy (DURAVYU) targeting the following condition: In patients with non-proliferative diabetic retinopathy (NPDR).. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Arbutus Biopharma FDA EventsAcumen Pharmaceuticals FDA EventsCognition Therapeutics FDA EventsCorbus Pharmaceuticals FDA EventsDiaMedica Therapeutics FDA EventsGilead Sciences FDA EventsSCYNEXIS FDA EventsSciSparc FDA EventsAbbVie FDA EventsMedtronic FDA EventsTeleflex FDA EventsAchieve Life Sciences FDA EventsBioCryst Pharmaceuticals FDA EventsHeartBeam FDA EventsCardiff Oncology FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Harrow FDA Events Avalyn Pharma FDA Events Theravance Biopharma FDA Events Cybin FDA Events Spyglass Pharma FDA Events Ardelyx FDA Events Achieve Life Sciences FDA Events Collegium Pharmaceutical FDA Events Aquestive Therapeutics FDA Events CorMedix FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:EYPT last updated on 10/19/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s Next Partnership: Buy This Stock NowElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredBeginner’s Guide to GoldInflation, trade wars, and market volatility have many savers rethinking how they protect retirement funds. A ...Goldco Direct, LLC | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eyepoint Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Positive Results - October 19,2026Positive Results Phase 3Drug: DURAVYUAnnounced Date: October 19, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).Read Announcement
NDA submission - August 17,2026Nda Submission Drug: DURAVYUAnnounced Date: August 17, 2026Target Action Date: H1 2027Estimated Target Date Range: January 1, 2027 - June 30, 2027Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the potential FDA New Drug Application submission planned for 1H 2027Read Announcement
Top-line data - August 17,2026Top-Line Data Drug: DURAVYUAnnounced Date: August 17, 2026Target Action Date: Q4 2026Estimated Target Date Range: October 1, 2026 - December 31, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the Topline data from LUCIA, the second pivotal Phase 3 clinical trial in wet AMD, expected in Q4 2026Read Announcement
Top-line results - August 17,2026Top-Line Results Phase 3Drug: DURAVYUAnnounced Date: August 17, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced topline results from LUGANO, the first pivotal Phase 3 clinical trial for DURAVYU™ (vorolanib intravitreal insert) for the treatment of wet age-related macular degeneration (wet AMD).Read Announcement
Top-line data - July 30,2026Top-Line Data Drug: DURAVYUAnnounced Date: July 30, 2026Target Action Date: Q4 2027Estimated Target Date Range: October 1, 2027 - December 31, 2027Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that Topline data for both DME trials are anticipated in the fourth quarter of 2027.AI SummaryEyePoint, Inc. announced that its COMO and CAPRI clinical trials for DURAVYU in diabetic macular edema (DME) rapidly enrolled more than 480 participants within five months. The company said the strong enrollment reflects continued interest from retinal specialists and patients in participating in DURAVYU studies. Topline 56-week data from both DME trials are anticipated in the fourth quarter of 2027. These results are expected to provide important information about DURAVYU’s effectiveness and safety over nearly one year of treatment. DURAVYU is being studied as a potential long-acting treatment for DME, a condition in which diabetes causes swelling in the retina and can impair vision. Earlier clinical studies of DURAVYU in wet age-related macular degeneration and DME reported stable vision and control of retinal anatomy after a single dose. EyePoint is developing the treatment in partnership with the retina community and aims to reduce treatment burdens for patients who may require repeated eye injections.Read Announcement
Enrollment Update - July 30,2026Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: July 30, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced it has completed enrollment in COMO and CAPRI, the two global Phase 3 clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). Over 480 patients have been enrolled across both trials, with full enrollment occurring ahead of schedule, in only five months.AI SummaryEyePoint, Inc. announced that it has completed enrollment in COMO and CAPRI, two global Phase 3 clinical trials evaluating DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). Together, the trials enrolled more than 480 patients in just five months, finishing ahead of schedule. The rapid enrollment reflects strong interest in participating among retinal specialists and patients. Topline results from both studies are expected in the fourth quarter of 2027, after 56 weeks of follow-up. DURAVYU is designed to provide localized treatment in the eye and is being studied for its potential to help control vision loss and retinal changes linked to DME. Earlier Phase 1 and Phase 2 studies in DME and wet age-related macular degeneration showed stable vision and anatomical control after a single dose, with no safety signals reported in more than 190 patients across four completed trials. DURAVYU remains investigational and is not approved for use.Read Announcement
review - May 14,2026Review Data Safety Monitoring Committee (DSMC)Drug: DURAVYUAnnounced Date: May 14, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced that the independent Data Safety Monitoring Committee (DSMC) completed its third scheduled review of the Company's pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD) and recommended that both the LUGANO and LUCIA trials continue as planned with no protocol modifications.AI SummaryEyePoint, Inc. said the independent Data Safety Monitoring Committee finished its third scheduled review of the Phase 3 DURAVYU program for wet age-related macular degeneration and recommended that both the LUGANO and LUCIA trials continue as planned, with no changes to the study design. The company said the masked data still show a favorable safety profile, matching results from four earlier clinical trials. It also noted that all active patients in the treatment group have reached their second dosing visit, and more than 35% have received a third dose. EyePoint said LUGANO topline data are still expected in mid-2026, with LUCIA results to follow soon after. DURAVYU remains an investigational treatment and has not been approved. The company said earlier studies showed stable vision and eye anatomy control, with no drug-related safety concerns seen in more than 190 patients.Read Announcement
Dose Update - March 2,2026Dose Update Phase 3Drug: DURAVYUAnnounced Date: March 2, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint, Inc. announced the first patient dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).AI SummaryEyePoint, Inc. announced the first patient has been dosed in both Phase 3 COMO and CAPRI global clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). The company is running active Phase 3 programs for DURAVYU in wet age-related macular degeneration (wet AMD) and DME, two of the largest multi‑billion‑dollar retinal disease markets. These global studies aim to confirm the treatment’s benefit for patients with vision-threatening retinal disease. Topline data for DURAVYU in DME is anticipated in the second half of 2027. Earlier Phase 1 and 2 trials showed safety and efficacy signals, with single-dose treatment demonstrating stability in vision and anatomical control. Across four completed trials involving over 190 patients, no safety signals were observed. EyePoint states it remains focused on working with the retina community to advance this investigational treatment. Read Announcement
review - November 19,2025Review Data Safety Monitoring Committee (DSMC)Drug: DURAVYUAnnounced Date: November 19, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced that the independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the Company's ongoing pivotal Phase 3 program evaluating DURAVYU for the treatment of wet age-related macular degeneration (wet AMD).AI SummaryEyePoint Pharmaceuticals said an independent Data Safety Monitoring Committee (DSMC) completed its second scheduled review of the pivotal Phase 3 program testing DURAVYU for wet age-related macular degeneration (wet AMD). As of the Sept. 29, 2025 data cutoff, all patients in the LUGANO and LUCIA trials had reached the Week 8 visit, when DURAVYU arms received their initial dose, and about 25% had received the planned second dose at Week 32. The DSMC recommended both trials continue as planned with no protocol changes. Masked safety data showed no safety signals and were consistent with earlier clinical trials. LUGANO and LUCIA are randomized, double‑masked, aflibercept‑controlled, non‑inferiority Phase 3 trials with enrollment complete (over 900 patients). Patients were randomized 1:1 to DURAVYU 2.7 mg every six months or on‑label aflibercept. EyePoint remains on track to report topline 56‑week LUGANO results in mid‑2026, with LUCIA results to follow closely. The DSMC meets every six months per protocol to monitor participant safety.Read Announcement
Provided Update - October 14,2025Provided Update Phase 3Drug: DURAVYUAnnounced Date: October 14, 2025Target Action Date: Q1 2026Estimated Target Date Range: January 1, 2026 - March 31, 2026Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced details for its pivotal Phase 3 program evaluating DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME) with first patient dosing anticipated in first quarter of 2026.AI SummaryEyePoint Pharmaceuticals announced its pivotal Phase 3 clinical program for DURAVYU™ (vorolanib intravitreal insert) to treat diabetic macular edema (DME), with first patient dosing expected in the first quarter of 2026. The program will include two identical non-inferiority trials, COMO and CAPRI, each enrolling about 240 patients. Both treatment-naïve and previously treated patients will be randomly assigned to a 2.7 mg DURAVYU arm or a 2 mg aflibercept control, with redosing every six months. The primary endpoint is the change from baseline in best corrected visual acuity (BCVA) at weeks 52 and 56 compared to aflibercept. New preclinical data show that vorolanib blocks vascular endothelial growth factor (VEGF)–mediated leakage and inhibits interleukin-6 (IL-6)–driven inflammation through JAK-1 receptor inhibition. This dual action supports the early and sustained improvements seen in the Phase 2 VERONA trial and highlights DURAVYU as a potential six-month, multi-mechanism treatment option for DME patients.Read Announcement
Enrollment Update - July 29,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: July 29, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced it has completed enrollment of its Phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal non-inferiority trials evaluating DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD). The first pivotal trial, LUGANO, completed enrollment in May 2025.AI SummaryEyePoint Pharmaceuticals has finished enrolling the LUCIA trial, the second of two Phase 3 non-inferiority studies testing DURAVYU for wet age-related macular degeneration. The first trial, LUGANO, completed enrollment in May 2025. LUCIA enrolled over 400 patients in seven months, bringing the combined total to more than 800 and making it one of the fastest Phase 3 wet AMD programs. An independent Data Safety Monitoring Committee reviewed interim safety data and saw no new risks. They confirmed the trials should continue as planned. DURAVYU’s safety profile remained consistent with earlier clinical studies, with no drug-related serious eye or systemic adverse events reported. EyePoint expects interim data from LUGANO’s 56-week analysis in mid-2026, with LUCIA topline results soon after. Both trials test six-month dosing of DURAVYU versus on-label aflibercept, measuring vision, safety, and treatment burden.Read Announcement
Enrollment Update - May 27,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: May 27, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced it has enrolled and randomized over 400 patients in the Phase 3 LUGANO pivotal trial of DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD) exceeding its enrollment target.AI SummaryEyePoint Pharmaceuticals has surpassed its enrollment target in the Phase 3 LUGANO pivotal trial for DURAVYU™, a sustained-release treatment for wet age-related macular degeneration (wet AMD). More than 400 patients have been enrolled and randomized over a seven-month period—a record pace for a Phase 3 trial in this field. This rapid enrollment reflects strong interest from both physicians and patients, highlighting the significant need for improved treatment options in wet AMD. The LUGANO trial, which is one of two non-inferiority trials in EyePoint’s Phase 3 program for DURAVYU, aims to assess the drug’s safety and efficacy. With top-line 56-week data expected in mid-2026, the timely progress of this trial, along with the upcoming LUCIA trial enrollment, underscores the potential impact of DURAVYU in transforming the current treatment paradigm for wet AMD.Read Announcement
Provided Update - March 5,2025Provided Update Drug: DURAVYUAnnounced Date: March 5, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc highlighted recent corporate developments.AI SummaryEyePoint Pharmaceuticals, Inc. recently announced its financial results for Q4 and the full year ended December 31, 2024, along with key corporate developments. The company emphasized that its sustained delivery therapy, DURAVYU™, is progressing well in clinical trials for two major retinal diseases. The Phase 3 wet AMD trials, LUGANO and LUCIA, are exceeding enrollment expectations, with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule. Positive Phase 2 data from the VERONA trial in diabetic macular edema also met primary and secondary endpoints. Additionally, EyePoint highlighted its strong financial position, reporting $371 million in cash and investments as of December 31, 2024, which is expected to support operations into 2027. These developments underscore the company’s commitment to advancing DURAVYU™ and position it for potential future regulatory and commercial success.Read Announcement
Enrollment Update - February 25,2025Enrollment Update Phase 3Drug: DURAVYUAnnounced Date: February 25, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc. announced that Jay S. Duker, M.D., EyePoint's President and CEO, will present an update on enrollment for its ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD) and additional subgroup analyses for the Phase 2 VERONA trial for DURAVYU in diabetic macular edema (DME) at the TD Cowen 45th Annual Health Care Conference.AI SummaryEyePoint Pharmaceuticals announced that its President and CEO, Dr. Jay S. Duker, will share updates on DURAVYU™ during a corporate presentation. The presentation is set for Tuesday, March 4, 2025 at 9:10 a.m. ET at the TD Cowen 45th Annual Health Care Conference. Dr. Duker will provide an update on enrollment for the ongoing Phase 3 pivotal program of DURAVYU in wet age-related macular degeneration (wet AMD). Additionally, he will discuss subgroup analyses from the Phase 2 VERONA trial, which tested DURAVYU for diabetic macular edema (DME). This update is important as it gives insight into the progress of the clinical trials for DURAVYU, an investigational product aimed at treating serious retinal diseases. The live webcast and archived presentation can be accessed on the company’s website. Read Announcement
Provided Update - February 5,2025Provided Update Phase 3Drug: DURAVYUAnnounced Date: February 5, 2025Target Action Date: LATE 2025Estimated Target Date Range: October 1, 2025 - December 31, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc Phase 3 non-inferiority pivotal program initiation anticipated by the end of 2025AI SummaryEyePoint Pharmaceuticals has reported encouraging Phase 2 results for its investigational therapy DURAVYU, a sustained delivery treatment for diabetic macular edema. In the trial, both investigated doses met the primary endpoint by extending the time to a needed supplemental injection compared to the current treatment. In particular, the 2.7mg dose showed early and sustained improvements in vision and retinal anatomy while also reducing the overall treatment burden. The positive outcomes were paired with a favorable safety profile, with no serious ocular or systemic adverse events related to DURAVYU. Building on these promising findings, the company anticipates launching a Phase 3 non-inferiority pivotal clinical program by the end of 2025, aiming to further validate DURAVYU’s potential as a best-in-class treatment option for serious retinal diseases.Read Announcement
Positive Results - February 5,2025Positive Results Phase 2Drug: DURAVYUAnnounced Date: February 5, 2025Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced positive six-month results for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU™ (vorolanib intravitreal insert), an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor (TKI) formulated in proprietary bioerodible Durasert E™.AI SummaryEyePoint Pharmaceuticals announced positive six-month results from the ongoing Phase 2 VERONA trial evaluating DURAVYU™, an investigational sustained delivery therapy that uses patent-protected vorolanib delivered via its proprietary bioerodible Durasert E™ system. Both tested doses, 1.34 mg and 2.7 mg, achieved the primary endpoint by extending the time to the first supplemental injection compared to an aflibercept control. The 2.7 mg dose, in particular, showed an early and sustained improvement in visual acuity with a 7.1-letter gain in BCVA at 24 weeks, along with a 76-micron reduction in central subfield thickness. The study also reported a significant decrease in treatment burden and maintained a favorable safety profile with no observed DURAVYU-related ocular or systemic serious adverse events. These promising outcomes support plans to initiate a Phase 3 non-inferiority pivotal program later in 2025.Read Announcement
Dose Update - December 4,2024Dose Update Phase 3Drug: DURAVYUAnnounced Date: December 4, 2024Indication: In patients with non-proliferative diabetic retinopathy (NPDR).AnnouncementEyePoint Pharmaceuticals, Inc announced that the first patient has been dosed in the LUCIA trial, the Company's second global Phase 3 clinical trial of DURAVYU, formerly EYP-1901, for the treatment of wet age-related macular degeneration (wet AMD).AI SummaryEyePoint Pharmaceuticals has dosed the first patient in the LUCIA trial, its second global Phase 3 study for DURAVYU (formerly EYP-1901) in treating wet age-related macular degeneration (wet AMD). DURAVYU is an investigational therapy that delivers vorolanib steadily through a bioerodible implant. The new trial follows closely on the heels of the ongoing LUGANO trial, demonstrating the company’s strong commitment to exploring sustained drug delivery for retinal diseases. The LUCIA trial aims to gather data on the drug’s safety, effectiveness, and dosing flexibility, potentially easing the treatment burden for wet AMD patients who often require frequent injections. With enthusiastic support from physicians and patients around the globe, EyePoint is optimistic that these Phase 3 trials will help change the current treatment landscape for wet AMD and offer more durable treatment options.Read Announcement
